Scientific Progress

Thanks to the rapid progress in science over the course of the last decades we are able to offer our ambitious products to customers worldwide.

TICEBA - Company - Scientific Progress - Picture 01TICEBA - Company - Scientific Progress - Picture 02

The 21st century will be a century of biology and medicine. Tissue engineering (reconstruction of tissue) will be one of the key technologies. This still fledgling branch of medicine is among others dealing with the reproduction of tissue and whole organs from adult stem cells.

These adult stem cells have a decisive repair function. They are able to replace defective cells and allow for the organ or cell structure to be able to again carry out its original function.

Tissue engineering aims at "repairing" body tissue and organs with the help of adult stem cells and to thereby re-establish their natural function or to maintain it over longer time periods than ever before.

It is TICEBA's aim to offer its customers the possibility to retrieve their own healthy stem cells whenever they are needed for this kind of healing process.

News
Coronavirus and Mesenchymal Stem Cells

Therapy for Pneumonia Patients infected by 2019 Novel Coronavirus

Treatment With Mesenchymal Stem Cells for Severe Corona Virus Disease 2019(COVID-19)

Mesenchymal Stem Cell Treatment for Pneumonia Patients Infected With 2019 Novel Coronavirus

Article about our study with limbal stem cells

On the website of the Harvard Stem Cell Institute you will find the following news release about the ongoing clinical trial conducted by our daughter company RHEACELL in patients suffering from limbal stem cell deficiency: Restoring vision: A stem cell therapy for cornea regeneration reaches the clinical-trial stage.

Clinical Trial - EB

The international phase I/IIa clinical trial has been approved by the U.S. Food and Drug Administration (FDA) and several European competent national regulatory authorities. The medicinal drug product tested in this trial has recently been granted Orphan Drug designation from the FDA and the European Medicines Agency (EMA) for the treatment of EB.

Clinical Trial - LSCD

The international phase I/IIa clinical trial has been approved by the U.S. Food and Drug Administration (FDA) and the German regulatory authority (Paul Ehrlich Institute). The medicinal drug product tested in this trial has recently been granted Orphan Drug designation from the FDA and the European Medicines Agency (EMA) and Fast Track designation from the FDA for the treatment of LSCD.

Safety

In a comprehensive preclinical study program, safety and local tolerability of ABCB5+ MSCs following subcutaneous, intramuscular and intravenous application has been demonstrated (Tappenbeck et al., 2019).

Newsletter